Q3 2025 EPS Estimates for Novartis AG (NYSE:NVS) Decreased by Analyst

Novartis AG (NYSE:NVS) – Research analysts at Zacks Research cut their Q3 2025 earnings per share (EPS) estimates for Novartis in a research note issued on Monday, April 22nd. Zacks Research analyst E. Bagri now expects that the company will post earnings of $1.98 per share for the quarter, down from their previous forecast of $1.99. The consensus estimate for Novartis’ current full-year earnings is $7.13 per share.

Novartis (NYSE:NVS) last released its quarterly earnings results on Tuesday, January 30th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The firm had revenue of $11.42 billion for the quarter, compared to analyst estimates of $11.69 billion. Novartis had a return on equity of 29.90% and a net margin of 29.83%. During the same period last year, the firm earned $1.51 EPS.

Several other research firms have also commented on NVS. BMO Capital Markets lifted their price target on Novartis from $114.00 to $116.00 and gave the stock a “market perform” rating in a research report on Wednesday. Morgan Stanley began coverage on Novartis in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $114.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Novartis has a consensus rating of “Moderate Buy” and a consensus target price of $115.00.

Novartis Trading Up 1.1 %

NVS opened at $98.35 on Wednesday. The firm has a market cap of $201.03 billion, a price-to-earnings ratio of 13.70, a price-to-earnings-growth ratio of 1.55 and a beta of 0.54. Novartis has a 52 week low of $92.19 and a 52 week high of $108.78. The business’s 50 day moving average is $97.93 and its two-hundred day moving average is $98.99. The company has a quick ratio of 0.93, a current ratio of 1.15 and a debt-to-equity ratio of 0.39.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the stock. Murphy Middleton Hinkle & Parker Inc. raised its position in Novartis by 4.9% in the fourth quarter. Murphy Middleton Hinkle & Parker Inc. now owns 2,072 shares of the company’s stock worth $209,000 after acquiring an additional 97 shares in the last quarter. Pinnacle Bancorp Inc. increased its holdings in shares of Novartis by 2.8% in the 4th quarter. Pinnacle Bancorp Inc. now owns 3,641 shares of the company’s stock valued at $368,000 after purchasing an additional 98 shares in the last quarter. Optimum Investment Advisors lifted its stake in shares of Novartis by 23.3% in the fourth quarter. Optimum Investment Advisors now owns 530 shares of the company’s stock valued at $54,000 after purchasing an additional 100 shares during the period. Chesley Taft & Associates LLC lifted its stake in shares of Novartis by 0.3% in the fourth quarter. Chesley Taft & Associates LLC now owns 33,062 shares of the company’s stock valued at $3,338,000 after purchasing an additional 100 shares during the period. Finally, Means Investment CO. Inc. boosted its holdings in Novartis by 1.3% during the fourth quarter. Means Investment CO. Inc. now owns 8,074 shares of the company’s stock worth $815,000 after buying an additional 103 shares in the last quarter. 13.12% of the stock is currently owned by hedge funds and other institutional investors.

Novartis Increases Dividend

The business also recently announced an annual dividend, which was paid on Thursday, March 7th. Shareholders of record on Friday, March 8th were paid a $3.7772 dividend. This is an increase from Novartis’s previous annual dividend of $3.47. This represents a dividend yield of 3.1%. The ex-dividend date of this dividend was Thursday, March 7th. Novartis’s dividend payout ratio (DPR) is 33.84%.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.